Rxcurve
HCPCS J3402 · per Per Therapeutic Dose

Inj. remestemcel-l-rknd/ td

Products billed under this code include Ryoncil.

Payment limit per Per Therapeutic Dose, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J3402

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Ryoncil Mesoblast, Inc. 73648-0111-01 1 $202,159.938
Ryoncil Mesoblast, Inc. 73648-0112-02 1 $202,159.938
Ryoncil Mesoblast, Inc. 73648-0113-03 1 $202,159.938
Ryoncil Mesoblast, Inc. 73648-0114-01 1 $202,159.938
Ryoncil Mesoblast, Inc. 73648-0115-02 1 $202,159.938
Ryoncil Mesoblast, Inc. 73648-0116-03 1 $202,159.938
Ryoncil Mesoblast, Inc. 73648-0117-04 1 $202,159.938
Ryoncil Mesoblast, Inc. 73648-0118-02 1 $202,159.938
Ryoncil Mesoblast, Inc. 73648-0122-03 1 $202,159.938

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $202,159.938 −$1,499.825 Per Therapeutic Dose Inj. remestemcel-l-rknd/ td v1, posted September 17, 2026
3Q26 $203,659.763 +$946.179 Per Therapeutic Dose Inj. remestemcel-l-rknd/ td v1, posted September 15, 2026
2Q26 $202,713.584 +$1,044.563 Per Therapeutic Dose Inj. remestemcel-l-rknd/ td v1, posted September 15, 2026
1Q26 $201,669.021 −$3,970.979 Per Therapeutic Dose Inj. remestemcel-l-rknd/ td v1, posted September 15, 2026
4Q25 $205,640.00 – Per Therapeutic Dose Inj. remestemcel-l-rknd/ td v1, posted September 8, 2026

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files